SPRY NASDAQ
ARS Pharmaceuticals, Inc.
1W: +3.6%
1M: -2.0%
3M: -8.6%
YTD: -28.4%
1Y: -42.6%
3Y: +0.7%
5Y: -69.0%
$7.94
-0.29 (-3.52%)
Weekly Expected Move ±8.3%
$6
$7
$7
$8
$9
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$788.5M
52W Range6.66-18.9
Volume2,430,895
Avg Volume1,600,576
Beta0.80
Dividend—
Analyst Ratings
Company Info
CEORichard E. Lowenthal
Employees155
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-04
Websitears-pharma.com
3525 Del Mar Heights Road
San Diego, CA 92130
US
San Diego, CA 92130
US
858 335 1300
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Latest News
Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program
ARS Pharma (SPRY) Q4 2025 Earnings Transcript
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Scott Kathleen D. | A-Award | 240,000 | $11.49 | 2026-01-02 |
| Karas Eric | A-Award | 240,000 | $11.49 | 2026-01-02 |
| Fitzpatrick Alexande | A-Award | 240,000 | $11.49 | 2026-01-02 |
| Dorsey Brian | A-Award | 240,000 | $11.49 | 2026-01-02 |
| Chakma Justin | A-Award | 240,000 | $11.49 | 2026-01-02 |